CV biotech catalysts & pipeline

CAPSOVISION INC · Data as of 2026-10-25

Upcoming catalysts

CapsoCam Colon — Regulatory decision

Q4 2026

This revision impacts the previous expectation to have the study for the Second-Generation Product ready for FDA submission in the first quarter 2026 and the FDA submission is now planned for the second quarter of 2026, with a goal of obtaining FDA 510(k) clearance for the Second-Generation Product in the fourth quarter of 2026.

Source filing

CapsoCam Colon — NDA/BLA submission

Q4 2026

Pipeline continues to advance with CapsoCam Colon™ on track for 510(k) submission in the fourth quarter of 2026, with ongoing enrollment in the CapsoCam UGI clinical study for pancreatic cancer detection.

Source filing

Explore the free biotech catalyst calendar